As glucose levels increased, sepsis-related mortality also increased: 0.9% in the euglycemic group, 3.5% in the mild hyperglycemia group, and 19.3% in the overt hyperglycemia group. Hyperglycemia is a ...

Intercept Pharmaceuticals, the developer of the PBC drug, suggested that the company's view on the drug's benefit and risk profile differed from that of the US Food and Drug Administration.

Results support incorporating discussions of adverse events alongside efficacy in shared treatment decision-making. Progression-free survival (PFS) and the impact of adverse events (AEs) on quality of ...

The patient was diagnosed with primary diffuse large B-cell lymphoma (DLBCL) of the optic nerve based on histopathologic analysis of biopsy. Researchers from Poland reported the case of a patient with ...

Nipocalimab is currently being evaluated in 2 international randomized studies for HDFN: the UNITY and AZALEA trials. With nearly 1000 times greater affinity for FcRn than intravenous immunoglobulin, ...

Immunohistochemistry can identify concomitant SM in acute myeloid leukemia, leading to better risk stratification and management. The most common forms of AML in pediatric patients are those ...

Intravenous immunoglobulin-induced thrombocytopenia was reported in 146 cases, with the highest incidence seen in patients with immune-mediated skin diseases. Intravenous immunoglobulin (IVIg) therapy ...

Dan Lier has light chain (AL) amyloidosis—the most common form of amyloidosis. Larry Luxner, senior correspondent for Rare Disease Advisor, interviews former college basketball player Dan Lier, a ...

Jerry Lewis, one of the most famous comedians of the 20th century, was a tireless advocate for people with muscular dystrophy. Larry Luxner, senior correspondent for Rare Disease Advisor, interviews ...

In CIDP, SOC therapies (immunoglobulins/corticosteroids) are burdensome, have variable efficacy, and significant side-effects. Two phase 3 clinical trials, MOBILIZE ...

Approximately 42% of patients showed evidence of SMN1 to SMN2 conversion, confirmed by the presence of SMN1-specific variants downstream of SMN2. To shed more light on the genetic determinants of SMA ...

The primary outcome measure of the study includes determining the dose-limiting toxicity as well as the maximal tolerated dose. A clinical trial aiming to determine the efficacy, safety, and ...